Integra LifeSciences (NASDAQ:IART) Shares Cross Above 200 Day Moving Average – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.10 and traded as high as $15.15. Integra LifeSciences shares last traded at $14.82, with a volume of 1,174,234 shares trading hands.

Analyst Upgrades and Downgrades

IART has been the subject of a number of analyst reports. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating for the company in a research report on Thursday, October 22nd. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Zacks Research downgraded shares of Integra LifeSciences from a “hold” rating to a “strong sell” rating in a report on Monday, October 26th. Wells Fargo & Company set a $13.00 price objective on Integra LifeSciences and gave the company an “equal weight” rating in a research note on Thursday, October 22nd. Finally, BMO Capital Markets restated a “market perform” rating and issued a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus price target of $16.12.

Integra LifeSciences Trading Down 5.0%

The firm has a market capitalization of $1.04 billion, a P/E ratio of 78.94, a price-to-earnings-growth ratio of 0.53 and a beta of 1.28. The firm has a 50-day moving average of $14.55 and a 200-day moving average of $14.12. The company has a debt-to-equity ratio of 1.67, a quick ratio of 2.21 and a current ratio of 3.62.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to the consensus estimate of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same quarter in the prior year, the company earned ($0.07) earnings per share. On average, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Paradigm Capital Management Inc. NY grew its holdings in Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares in the last quarter. Wellington Management Group LLP grew its holdings in Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares in the last quarter. Bank of America Corp DE increased its stake in Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA raised its holdings in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares in the last quarter. Finally, Access Investment Management LLC raised its holdings in shares of Integra LifeSciences by 72.0% during the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after acquiring an additional 268,085 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.